We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-17.86%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.5M
AUM Growth
+$26M
Cap. Flow
+$35.8M
Cap. Flow %
37.05%
Top 10 Hldgs %
76.97%
Holding
60
New
14
Increased
12
Reduced
2
Closed
28

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$12.8M
2
VTRS icon
Viatris
VTRS
+$6.56M
3
CELG
Celgene Corp
CELG
+$5.66M
4
AGN
Allergan plc
AGN
+$5.24M
5
SNY icon
Sanofi
SNY
+$4.7M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$5.49M
2
ABBV icon
AbbVie
ABBV
+$3.64M
3
BMY icon
Bristol-Myers Squibb
BMY
+$2.84M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$1.98M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$807K

Sector Composition

Rank Sector Weight
1 Healthcare 89.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNX
26
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$419K 0.43%
+96,000
New +$428K
CYNA
27
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$401K 0.42%
+33,716
New +$452K
TMBR
28
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$377K 0.39%
+23
New +$521K
TBRA
29
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$368K 0.38%
45,000
+10,000
+29% +$75.4K
XNPT
30
DELISTED
XENOPORT, INC.
XNPT
$361K 0.37%
+80,000
New +$369K
NERV icon
31
Minerva Neurosciences
NERV
$199M
$209K 0.22%
4,263
– –
ABBV icon
32
AbbVie
ABBV
$465B
– –
-61,500
Closed -$3.64M
DARE icon
33
Dare Bioscience
DARE
$17.8M
– –
-417
Closed -$140K
DRRX
34
DELISTED
DURECT Corp
DRRX
– –
-28,151
Closed -$622K
HRTX icon
35
Heron Therapeutics
HRTX
$92M
– –
-23,600
Closed -$630K
INO icon
36
Inovio Pharmaceuticals
INO
$84.7M
– –
-5,000
Closed -$403K
KMDA icon
37
Kamada
KMDA
$407M
– –
-72,000
Closed -$302K
MRK icon
38
Merck
MRK
$326B
– –
-108,992
Closed -$5.49M
RCKT icon
39
Rocket Pharmaceuticals
RCKT
$343M
– –
-10,500
Closed -$476K
RDHL
40
Redhill Biopharma
RDHL
$4.44M
– –
-24
Closed -$309K
SCYX icon
41
SCYNEXIS
SCYX
$36M
– –
-496
Closed -$246K
CDMO
42
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-35,000
Closed -$287K
NTBL
43
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
– –
-952
Closed -$175K
MRNS
44
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-6,250
Closed -$191K
ZYNE
45
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-15,000
Closed -$151K
SRRA
46
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-500
Closed -$301K
GWPH
47
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-5,000
Closed -$347K
NEOS
48
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-15,000
Closed -$215K
FCSC
49
DELISTED
Fibrocell Science Inc.
FCSC
– –
-2,000
Closed -$137K
ALDR
50
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-60,000
Closed -$1.98M
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Nexthera Capital held 60 positions worth $96.5M, up 37% from $70.5M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Nexthera Capital deployed $35.8M of net new capital in Q1 2016, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Shire pic: 76,200 shares worth $13.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $2.84M trimmed.

  • Nexthera Capital's largest Q1 2016 buy was Shire pic: 76,200 shares worth $13.1M.
  • Nexthera Capital added most to Celgene Corp in Q1 2016, an estimated $5.66M increase.
  • Nexthera Capital's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $2.84M.
  • Nexthera Capital fully exited Merck in Q1 2016, selling an estimated $5.49M.
  • Nexthera Capital's ten largest holdings make up 77% of its $96.5M portfolio in Q1 2016.
  • Nexthera Capital opened 14 new positions and closed 28 in Q1 2016.
  • Nexthera Capital's portfolio value rose 37% quarter-over-quarter to $96.5M.

Based on Nexthera Capital's 13F filing for Q1 2016, filed 13 May 2016.